Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update

M. A. Martin, J. M. Hoffman, Robert Freimuth, T. E. Klein, B. J. Dong, M. Pirmohamed, J. K. Hicks, M. R. Wilkinson, D. W. Haas, D. L. Kroetz

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

Original languageEnglish (US)
Pages (from-to)499-500
Number of pages2
JournalClinical Pharmacology and Therapeutics
Volume95
Issue number5
DOIs
StatePublished - 2014

Fingerprint

HLA-B Antigens
Pharmacogenetics
Genotype
Guidelines
Electronic Health Records
Publications
abacavir
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing : 2014 update. / Martin, M. A.; Hoffman, J. M.; Freimuth, Robert; Klein, T. E.; Dong, B. J.; Pirmohamed, M.; Hicks, J. K.; Wilkinson, M. R.; Haas, D. W.; Kroetz, D. L.

In: Clinical Pharmacology and Therapeutics, Vol. 95, No. 5, 2014, p. 499-500.

Research output: Contribution to journalArticle

Martin, MA, Hoffman, JM, Freimuth, R, Klein, TE, Dong, BJ, Pirmohamed, M, Hicks, JK, Wilkinson, MR, Haas, DW & Kroetz, DL 2014, 'Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update', Clinical Pharmacology and Therapeutics, vol. 95, no. 5, pp. 499-500. https://doi.org/10.1038/clpt.2014.38
Martin, M. A. ; Hoffman, J. M. ; Freimuth, Robert ; Klein, T. E. ; Dong, B. J. ; Pirmohamed, M. ; Hicks, J. K. ; Wilkinson, M. R. ; Haas, D. W. ; Kroetz, D. L. / Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing : 2014 update. In: Clinical Pharmacology and Therapeutics. 2014 ; Vol. 95, No. 5. pp. 499-500.
@article{81a074e0dbc94b448105084638c3f18c,
title = "Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update",
abstract = "The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).",
author = "Martin, {M. A.} and Hoffman, {J. M.} and Robert Freimuth and Klein, {T. E.} and Dong, {B. J.} and M. Pirmohamed and Hicks, {J. K.} and Wilkinson, {M. R.} and Haas, {D. W.} and Kroetz, {D. L.}",
year = "2014",
doi = "10.1038/clpt.2014.38",
language = "English (US)",
volume = "95",
pages = "499--500",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing

T2 - 2014 update

AU - Martin, M. A.

AU - Hoffman, J. M.

AU - Freimuth, Robert

AU - Klein, T. E.

AU - Dong, B. J.

AU - Pirmohamed, M.

AU - Hicks, J. K.

AU - Wilkinson, M. R.

AU - Haas, D. W.

AU - Kroetz, D. L.

PY - 2014

Y1 - 2014

N2 - The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

AB - The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

UR - http://www.scopus.com/inward/record.url?scp=84899417586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899417586&partnerID=8YFLogxK

U2 - 10.1038/clpt.2014.38

DO - 10.1038/clpt.2014.38

M3 - Article

C2 - 24561393

AN - SCOPUS:84899417586

VL - 95

SP - 499

EP - 500

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -